Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Replimune Group (NASDAQ:REPL) released its earnings results on Tuesday. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07, Zacks reports.

Replimune Group Price Performance

Replimune Group stock opened at $11.69 on Thursday. The business has a 50 day simple moving average of $11.44 and a 200 day simple moving average of $9.50. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The company has a market capitalization of $798.67 million, a PE ratio of -3.83 and a beta of 1.19. Replimune Group has a one year low of $4.92 and a one year high of $12.97.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Tuesday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Replimune Group has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.